Tralokinumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), DMC (Denmark) and HIRA (South Korea), among others, recommended or restricted tralokinumab, while NYE METODER (Norway) did not recommend it.
Where tralokinumab met resistance it was usually narrowed rather than refused: 4 of 10 decisive outcomes were recommendations with restrictions, against 2 outright refusals.
The record spans 2.6 years, opening at AWMSG (Wales) on 28 Apr 2021 and running to 9 Nov 2023.
HAS (France) changed its position: not recommended on 27 Oct 2021, recommended by 4 Oct 2023, after a resubmission.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
AWMSG (Wales) was first to assess tralokinumab, on 28 Apr 2021; HIRA (South Korea) did not open a file until 9 Nov 2023 — a moderate spread of 2.6 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 12 dated records fall in 2023 alone.
Restriction is doing real work here: 4 of 10 decisive outcomes narrowed tralokinumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), SMC (Scotland) and TLV (Sweden).
3 of the 9 agencies here assessed tralokinumab more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for tralokinumab.
The full ledger for tralokinumab reads 4 recommended, 4 restricted, 2 no benefit and 2 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 9 Nov 2023 | 성인 및 청소년 아토피 피부염 | reimbursement appropriate | source |
| AOTMIT (Poland) | 5 Jun 2023 | programu lekowego „Leczenie chorych Prezes Agencji rekomenduje objęcie refundacją produkt u leczniczego Adtralza (tralok… | recommended conditionally | source |
| G-BA (Germany) | 12 May 2023 | Adtralza — benefit assessment §35a | added benefit: not proven | source |
| NYE METODER (Norway) | 19 Jun 2022 | Behandling av moderat til alvorlig atopisk dermatitt hos voksne som er kandidater for systemisk behandling | not introduced | source |
| HAS (France) | 27 Oct 2021 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
8 further decisions for tralokinumab, across 7 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- susoctocog alfa — also decided by HIRA in 2023Q4
- trabectedin — also decided by HIRA in 2023Q4
- finerenone — also decided by HIRA in 2023Q4
- maribavir — also decided by HIRA in 2023Q4
- deucravacitinib — also decided by HIRA in 2023Q4
- beclometasone / formoterol / glycopyrronium — also decided by HIRA in 2023Q4
Coverage: 13 decisions for tralokinumab from 9 agencies, 2021 to 2023. Data to 7 Sep 2026. ATC class D11 — Other dermatologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.